UTHR United Therapeutics Corporation

559.10USD-3.16%Mkt Cap: 23.81B USDP/E: 21.11

United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationa…

Insiders, last 90 daysNet sellers
Institutional holders20 on file

Key Statistics

Company
Market Cap23.81B USD
Enterprise Value22.52B USD
Revenue (TTM)3.19B USD
Gross Profit2.80B USD
Net Income (TTM)1.33B USD
Revenue/Share74.08 USD
Last Price559.10 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees1.4K
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)21.11
P/E (Forward)16.61
PEG2.22
EV/EBITDA16.67
EV/Revenue7.07
P/S7.47
P/B3.78
EPS (TTM)26.49 USD
EPS (Forward)34.62 USD
52W Range
444.0468% of range614.23
52W High614.23 USD
52W Low444.04 USD
Profitability
Gross Margin87.92%
Oper. Margin39.38%
EBITDA Margin42.39%
Profit Margin41.94%
ROE18.81%
ROA16.94%
ROIC—
ROCE20.73%
Growth
Revenue Growth4.10%
Earnings Growth-20.30%
Cash Flow & Leverage
Operating CF1.56B USD
CapEx (TTM)526.00M USD
FCF Margin14.26%
FCF Yield1.91%
Net Debt-2.07B USD
Net Debt/EBITDA-1.53
Net Debt/FCF-4.55
Balance Sheet
Debt/Equity—
Current Ratio4.61
Quick Ratio3.87
Book Value/Sh148.08 USD
Cash/Share48.55 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split2:1
Split DateSep 23, 2009
Analyst Consensus
Rating1.7 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)687.14 USD
Upside (mean)+22.9%
Target Range390.00 USD – 850.00 USD
390.00+22.9% to mean850.00
# Analysts14
Ownership
Shares Out.42.59M
Float38.91M
Insiders2.06%
Institutions105.08%
Short Interest
Short Ratio2.1d
Short % Float5.04%
Short % Out.4.31%
Shares Short1.84M
Short (prev mo.)3.60M
Technical
SMA 50544.61 (+2.7%)
SMA 200538.05 (+3.9%)
Beta0.48
S&P 52W Chg12.08%
Avg Vol (30d)500.27K
Avg Vol (10d)529.31K
Technical Indicators
RSI (14)43.6
MACD6.4559
MACD Signal11.2621
MACD Hist.-4.8062
BB Upper612.71 USD
BB Middle587.18 USD
BB Lower561.65 USD
BB Width8.69%
ATR (14)18.28 USD
Vol Ratio (20d)0.81x

About United Therapeutics (NASDAQ: UTHR)

›

United Therapeutics (NASDAQ: UTHR) is listed on Nasdaq, where its shares trade in USD. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 1,400 employees.

The shares were at 559.10 USD on 19 November 2026, up 25.0% over 52 weeks. Its 52-week range is 444.04 USD to 614.23 USD: the price is 9.0% below the high and 25.9% above the low.

At a market capitalisation of 23.81B USD, it trades at 21.1 times trailing earnings and 16.6 times forward earnings. The median trailing P/E of its 17 largest Drug Manufacturers - Specialty & Generic peers is 26.3, a discount of 20% for UTHR.

United Therapeutics reports return on equity of 18.8%, an operating margin of 39.4% and revenue up 4.1% year over year.

It holds more cash than debt, a net cash position of 2.07B USD. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 14 analysts cover the stock, with an average rating of Buy; their mean price target of 687.14 USD is 22.9% above the current price. The next earnings report is expected on 24 February 2027.